The conversation is about hair loss treatment progress using finasteride and GHK-CU over six months. Users discuss application methods and share experiences with GHK-CU and AHK.
The conversation discusses CRISPR-on & CRISPR-off as a potential cure for baldness, contrasting it with hair cloning and other treatments like Minoxidil, finasteride, and RU58841. It also mentions the potential of mRNA for gene expression control and the prioritization of gene editing for severe genetic conditions.
The user has been using finasteride and minoxidil for 5 years to prevent hair loss and is considering adding dutasteride for regrowth or opting for a hair transplant. Suggestions include trying dutasteride, oral minoxidil, microneedling, and possibly a hair transplant for better results.
The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
Gut microbiota significantly influences androgen metabolism, impacting hair loss treatments like finasteride. Probiotics, dietary changes, and fecal microbiota transplants may help manage DHT levels and improve hair health.
The conversation discusses starting finasteride 1mg daily for hair loss and mentions a high baseline DHT level. Users comment on the unusually high DHT level and its potential causes.
The user is using finasteride, minoxidil, and dutasteride for hair loss, but stopped dutasteride due to side effects. They plan to have a hair transplant in December 2024 at Vanity Hospital in Istanbul, aiming for at least 4500 grafts.
Hair regrowth and gender transition using finasteride, estrogen, and spironolactone. Significant hair regrowth and personal transformation were achieved through hormone replacement therapy.
The user has been using oral finasteride for over a year and recently added GHK-CU for two months, seeing progress but seeking further improvement, especially on the hairline. They discuss sourcing GHK-CU, its effects, and the importance of third-party testing, while considering additional treatments like dutasteride and hair transplants for better results.
PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.
The conversation is about a user planning to undergo a hair transplant and seeking information on clinics that perform Verteporfin treatment. A user suggests Dr. Barghouthi might offer this service.
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.
A case study that suggests verteporfin may be able to help regrow donor hairs after FUE extraction, and the potential implications of this result. Treatments discussed include Minoxidil, Finasteride, and RU58841.
The user shared their 5-month hair progress using oral finasteride and minoxidil, reporting positive results with minimal side effects. They use a chewable 2-in-1 product from Hims for convenience.
The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.
The conversation discusses a new liposomal topical finasteride from Hasson and Wong, available in Canada and Italy, soon in the US, costing $40/month. It claims to reduce scalp DHT by 50% without affecting serum DHT, potentially benefiting those who can't tolerate oral finasteride or RU58841.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
GHK-Cu and AHK-Cu peptides show limited success for hair loss, with skepticism about their effectiveness and concerns about misleading claims. Users report better results when combined with treatments like finasteride, dutasteride, minoxidil, and other methods.
The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.
The conversation is about hair loss and correcting vitamin deficiencies, specifically D3, B12, and folic acid. The user is considering if these deficiencies impact hair growth and mentions starting supplements.
A user shared his experience of having two healthy children while continuously using finasteride (Fin) for hair loss, challenging fears about its potential impact on fetal development. The discussion that followed included various perspectives, with some users sharing similar experiences, others expressing concerns about potential risks, and some emphasizing the need for more substantial evidence before drawing conclusions.
A 46-year-old male shared his 3-week progress using HIMS serum with Finasteride 0.3% and Minoxidil 6%, showing improvement without noticeable shedding. His routine includes vitamins, a healthy diet, and specific hair care practices like microneedling and using caffeine solution.
A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.
Increasing IGF-1 may help hair growth, but it could also increase hair loss in people with high testosterone. Treatments discussed include l-arginine, glutamine, vanadium, Deer Antler Velvet, ATP, Cocarboxylase, l-carnitine, and Mk677.
A trans man is experiencing hair loss due to testosterone therapy but is unwilling to stop the treatment despite concerns about using finasteride. The individual is distressed about balding at a young age but acknowledges it is genetic.
The user has been using a combination of finasteride/dutasteride, minoxidil, tretinoin, and hydrocortisone with microneedling and ketoconazole shampoo for hair loss. They are asking if the baby hairs growing will turn into terminal hairs with continued treatment.